Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone Extension for PP-MS
NCT01854359Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2013
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idebenone in primary progressive multiple sclerosis (PPMS), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Area Under the Curve of the Combinatorial Weight-Adjusted Disability Score at 1 year. Started Mar 2013; status: completed.
02
Drugs
idebenone
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT01854359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01854359.